Louis DeGennaro
Showing 1–2 of 2 transcripts.
- Milken Institute1h 2m
Paying for Cures
Colleen Rye, Christiana Bardon, Louis DeGennaro, Joe La Barge, Mark Trusheim, Cynthia Verst, Cindy Virst, Mark Trusseimer, Chris Barden, Joe Medina, Eric Schmidt, Lou, Louis Kombolaini, John McWhorter, Tanisha Carino, Martha Minowski
Discussions on the evolution of curative gene therapies analyze the projected surge of over 500 pipeline candidates and the necessary shift from chronic treatment models to one-time cures that disrupt traditional pricing structures. Industry experts highlight innovative financial mechanisms, including outcomes-based rebates and installment payments, designed to navigate complex regulatory hurdles like Medicaid best price rules and FASB accounting volatility while addressing manufacturing costs. Despite significant challenges in social equity and international reimbursement disparities, the consensus suggests that historical precedents and market-driven competition will ultimately sustain a system capable of integrating these high-cost, durable medical breakthroughs.
- Milken Institute1h 1m
The Promise of the Cancer Moonshot
Kathy Hudson, Anna Barker, L. Michelle Bennett, Robert Bradway, Louis DeGennaro, Isla Garraway, Lou DiGennaro, Greg Simon, Tom Caleo, Jackie Brandwin, Greg Zuckerman, Laura Kalmos Nasser, Mike Hiltik, Noah Crafts
Following the Vice President's appointment to lead "Mission Control" and a proposed $1 billion federal funding request, the Cancer Moonshot initiative seeks to accelerate cancer research by prioritizing patient outcomes over bureaucratic processes. The program targets a structural shift from competition to collaboration through new mandates for data sharing, the launch of the Genomic Data Commons, and the implementation of patient-centric clinical trial designs. By leveraging public-private partnerships and modernizing regulatory frameworks, the initiative aims to bridge the gap between clinical trial success and real-world health equity within a 15-month timeline.